Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

ENTX

Entera Bio Ltd

Feb 05 • 11:29AM ET

2.32

Dollar change +0.02
Percentage change 0.87	%

Healthcare • Biotechnology • Israel • NASD

Peers: JNJ LLY AMGN BMY PFE SNY VRTX BIIB GSK NBIX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.26	Insider Own	19.38%	Shs Outstand	36.51M	Perf Week	-2.52%
Market Cap	85.45M	Forward P/E	-	EPS next Y	-0.55	Insider Trans	0.00%	Shs Float	29.70M	Perf Month	-13.75%
Income	-9.18M	PEG	-	EPS next Q	-0.08	Inst Own	26.64%	Short Float	0.32%	Perf Quarter	28.89%
Sales	0.10M	P/S	854.47	EPS this Y	9.68%	Inst Trans	4.52%	Short Ratio	0.66	Perf Half Y	56.76%
Book/sh	0.18	P/B	13.13	EPS next Y	-96.43%	ROA	-112.57%	Short Interest	0.10M	Perf Year	176.52%
Cash/sh	0.19	P/C	12.22	EPS next 5Y	-	ROE	-144.67%	52W Range	0.68 - 3.35	Perf YTD	9.43%
Dividend Est.	-	P/FCF	-	EPS past 5Y	25.05%	ROI	-139.08%	52W High	-30.75%	Beta	1.60
Dividend TTM	-	Quick Ratio	6.61	Sales past 5Y	-16.36%	Gross Margin	-17.17%	52W Low	241.13%	ATR (14)	0.19
Dividend Ex-Date	-	Current Ratio	6.61	EPS Y/Y TTM	24.52%	Oper. Margin	-9314.14%	RSI (14)	51.62	Volatility	9.51% 9.54%
Employees	37	Debt/Eq	0.05	Sales Y/Y TTM	607.14%	Profit Margin	-9270.71%	Recom	1.00	Target Price	10.00
Option/Short	Yes / Yes	LT Debt/Eq	0.02	EPS Q/Q	2.91%	Payout	-	Rel Volume	0.49	Prev Close	2.30
Sales Surprise	5.00%	EPS Surprise	-60.00%	Sales Q/Q	-	Earnings	Nov 08 AMC	Avg Volume	144.77K	Price	2.32
SMA20	-1.63%	SMA50	7.19%	SMA200	17.45%	Trades		Volume	24,479	Change	0.87%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-22-21	Initiated	Aegis Capital	Buy	$12

Jan-27-25 08:00AM	Entera Bio to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Nov-08-24 05:15PM	Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Entera Bio Reports Q3 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Sep-25-24 08:30AM	Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic Disorders (GlobeNewswire)
Sep-18-24 09:40AM	Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year? (Zacks)
09:40AM	Loading…
Sep-02-24 09:40AM	Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? (Zacks)
Aug-20-24 08:00AM	Entera Bio to Participate in Upcoming Investor and Scientific Conferences (GlobeNewswire)
Aug-15-24 12:00PM	All You Need to Know About Entera Bio (ENTX) Rating Upgrade to Buy (Zacks)
Aug-09-24 04:05PM	Entera Bio Reports Q2 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Aug-01-24 08:30AM	Entera's EB613, the First Once Daily PTH(1-34) Tablet Treatment Dedicated to Post-Menopausal Women with High Risk Osteoporosis Abstract Selected for Presentation at the ASBMR 2024 Annual Meeting - Key SABRE Update Also Expected (GlobeNewswire)
Jul-23-24 06:28AM	3 Meme Stocks to Buy and Hold for Potential 300% Returns in 3 Years (InvestorPlace)
Jul-08-24 03:53PM	3 Meme Stocks That Can Surge by 200% Before 2025 (InvestorPlace) +5.99%
Jul-02-24 05:05PM	3 Clinical-Stage Biotech Stocks to Buy for Multibagger Returns (InvestorPlace)
Jun-25-24 04:37PM	3 Meme Stocks to Buy on the Dip: June 2024 (InvestorPlace) -9.22%
Jun-20-24 12:38PM	7 Penny Stocks to Turn $3 Into $1 Million Within 36 Months (InvestorPlace)
06:47AM	Loading…
06:47AM	Rags to Riches: 3 Penny Stocks That Could Make Early Investors Rich (InvestorPlace)
06:47AM	Rag to Riches: 3 Penny Stocks That Could Make Early Investors Rich (InvestorPlace)
Jun-17-24 01:00PM	3 Penny Stocks to Turn $50,000 Into $1 Million: June 2024 (InvestorPlace)
Jun-10-24 07:22PM	Under-$10 Picks: 3 Biotech Stocks That Can Double Before the End of 2024 (InvestorPlace)
Jun-07-24 07:30AM	Meme Mania Meets Medicine: 3 Biotech Stocks Primed to Soar (InvestorPlace)
Jun-03-24 09:40AM	Has Entera Bio (ENTX) Outpaced Other Medical Stocks This Year? (Zacks)
08:00AM	Entera Bio Reports Phase 1 Clinical Data of First-in-Class, Oral PTH(1-34) Peptide Candidate (EB612) for Patients with Hypoparathyroidism at ENDO 2024 (GlobeNewswire)
May-23-24 06:45AM	The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom (InvestorPlace)
May-16-24 09:40AM	Are Medical Stocks Lagging Entera Bio (ENTX) This Year? (Zacks)
May-15-24 08:00AM	Entera Bio Appoints Dr. Rachel B Wagman as Key Clinical Advisor and Scientific Advisory Board Member (GlobeNewswire)
May-13-24 07:00AM	Entera Bio to Present Phase 1 Data from First-in-Class, PTH(1-34) Peptide Tablets (EB612) for the Treatment of Hypoparathyroidism at ENDO 2024 (GlobeNewswire)
May-10-24 08:53PM	ENTX Stock Earnings: Entera Bio Beats EPS for Q1 2024 (InvestorPlace)
04:10PM	Entera Bio Reports Q1 2024 Financial Results and Provides Business Updates (GlobeNewswire)
Apr-26-24 06:00PM	Entera Bio Ltd. (ENTX) Stock Slides as Market Rises: Facts to Know Before You Trade (Zacks)
Apr-18-24 06:15PM	Why the Market Dipped But Entera Bio Ltd. (ENTX) Gained Today (Zacks) -11.16%
03:43PM	Loading…
Apr-15-24 03:43PM	Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024? (InvestorPlace) -15.44%
Apr-12-24 09:40AM	Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year? (Zacks) +12.03%
Apr-09-24 09:09AM	Here's Why You Should Invest in Entera Bio (ENTX) Stock Now (Zacks) +15.38%
Apr-08-24 08:30AM	Entera Bio Announces Publication of Oral PTH(1-34) Peptide Tablets (EB613) Phase 2 Trial Data in the Journal of Bone and Mineral Research (GlobeNewswire)
Mar-26-24 08:30AM	Entera Bio Announces Key Regulatory Milestone for Oral PTH(1-34) Peptide (EB613) Phase 3 Program: FDA Ruling on Qualifying BMD as a Surrogate Endpoint for Osteoporosis Drugs is Expected Within 10 Months (GlobeNewswire)
Mar-24-24 03:54PM	12 Best Biotech Penny Stocks to Invest In (Insider Monkey)
Mar-20-24 08:00AM	Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome (GlobeNewswire) +7.79%
Mar-08-24 04:05PM	Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates (GlobeNewswire) +5.04%
Mar-04-24 08:30AM	Entera Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +19.44%
Jan-30-24 08:30AM	Entera Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-03-24 08:00AM	Entera Bio Receives Extension from Nasdaq to Regain Compliance with Minimum Bid Price Rule (GlobeNewswire)
Dec-26-23 08:00AM	Entera Bio Announces Closing of Private Placement - Extends Cash Runway into 2025 (GlobeNewswire)
Nov-29-23 08:30AM	Interim Results from Ongoing Clinical Study Confirm EB613 Optimized Profile for Osteoporosis Treatment and Potential for Entera's Next Generation Oral Peptide Platform (GlobeNewswire)
Nov-14-23 07:30AM	Entera Bio Reports Q3 2023 Financial Results, Highlights Transformational Steps and Unveils Vision as Premier Oral Peptide Company with Five Potential Programs in Development (GlobeNewswire)
Nov-09-23 02:30PM	Entera Bio Reports Key Milestone Relating to Oral PTH (1-34) Peptide (EB613) Phase 3 Program: ASBMR-SABRE Has Submitted to FDA the Full Qualification Plan to Approve BMD as a Surrogate Endpoint for Osteoporosis (GlobeNewswire) +20.64%
Oct-16-23 08:00AM	Entera Bio Reports Rapid Pharmacodynamic (PD) Response and Consistent Pharmacokinetic (PK) Data for its First-in-Class Oral PTH(1-34) Mini Tablets at the ASBMR 2023 Annual Meeting (GlobeNewswire)
Sep-13-23 01:18PM	OPKO Health (OPK) Ties Up for Oral Peptide Tablet Formulations (Zacks)
Sep-12-23 08:30AM	Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes (GlobeNewswire)
Sep-05-23 08:00AM	Entera Bio to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-16-23 08:30AM	Entera Bio to Present Two Abstracts on its First-in-Class, Once Daily Oral hPTH(1-34) Peptide Tablets (EB613) for the Treatment of Post-Menopausal Women at High Risk of Fracture at the American Society for Bone and Mineral Research (ASBMR) Annual Meeting (GlobeNewswire) +5.02%
Aug-11-23 04:05PM	Entera Bio Announces Q2 2023 Financial Results and Corporate Updates (GlobeNewswire) -17.57%
Jun-07-23 07:30AM	Entera Bio Adds Sanofi Commercial Leader, Haya Taitel to its Board of Directors (GlobeNewswire)
May-07-23 08:10AM	Entera Bio First Quarter 2023 Earnings: US$0.076 loss per share (vs US$0.13 loss in 1Q 2022) (Simply Wall St.)
May-05-23 05:15PM	Entera Bio Ltd. (ENTX) Reports Q1 Loss, Misses Revenue Estimates (Zacks) -6.70% +7.30%
04:05PM	Entera Bio Announces Q1 2023 Financial Results and Corporate Updates (GlobeNewswire)
May-04-23 10:00AM	Will Entera Bio Ltd. (ENTX) Report Negative Q1 Earnings? What You Should Know (Zacks)
May-03-23 09:34AM	Enteras Oral Delivery of GLP-2 Pre-Clinical Data to be Published in Peer Reviewed, International Journal of Peptide Research and Therapeutics (GlobeNewswire) +10.00%
Apr-26-23 08:30AM	Menopause Luminary, Dr. Steven R. Goldstein, Joins Enteras Clinical and Scientific Advisory Board (GlobeNewswire)
Apr-03-23 07:00AM	Entera Bio Provides Guidance from FDA Type D Meeting Related to EB613 Pivotal Program (GlobeNewswire) -13.36%
Mar-31-23 05:15PM	Entera Bio Ltd. (ENTX) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:00PM	Entera Bio Provides 2022 Corporate Milestones and Financial Results for the Year Ended December 31, 2022 (GlobeNewswire)
Mar-23-23 09:27AM	Entera Bio Regains Compliance with Nasdaq Listing Requirements (GlobeNewswire)
Mar-10-23 08:05AM	Will Entera Bio (NASDAQ:ENTX) Spend Its Cash Wisely? (Simply Wall St.)
Feb-20-23 08:34AM	Entera Bio (ENTX) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-15-23 10:00AM	Entera Bio Announces FDAs Acceptance of a Type D Meeting Review to Affirm Design of the Pivotal, Phase 3 Protocol for EB613 PTH Mini Tablets, as the First Oral Osteoanabolic Treatment of Post-Menopausal Osteoporosis (GlobeNewswire) +10.99%
Feb-13-23 09:00AM	Entera Bio to Participate in the SVB Securities Global Biopharma Conference (GlobeNewswire)
Feb-10-23 06:00PM	Entera Bio Ltd. (ENTX) Outpaces Stock Market Gains: What You Should Know (Zacks)
Feb-02-23 06:00PM	Entera Bio Ltd. (ENTX) Flat As Market Gains: What You Should Know (Zacks)
Jan-27-23 06:00PM	Entera Bio Ltd. (ENTX) Stock Sinks As Market Gains: What You Should Know (Zacks)
Jan-25-23 06:15PM	Entera Bio Ltd. (ENTX) Flat As Market Sinks: What You Should Know (Zacks)
Jan-18-23 06:15PM	Entera Bio Ltd. (ENTX) Gains As Market Dips: What You Should Know (Zacks)
Nov-16-22 07:27AM	New Strong Buy Stocks for November 16th (Zacks) +15.76%
Nov-10-22 05:45PM	Entera Bio Ltd. (ENTX) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -19.20%
04:15PM	Entera Bio Provides Corporate Updates and Financial Results for the Third Quarter of 2022 (GlobeNewswire)
Oct-06-22 07:00AM	Entera Bio Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support an NDA for EB613 for the Treatment of Osteoporosis (GlobeNewswire)
Oct-01-22 08:28AM	Is Entera Bio (NASDAQ:ENTX) In A Good Position To Invest In Growth? (Simply Wall St.)
Sep-21-22 08:30AM	Entera Bio Hosting Key Opinion Leader Webinar on the Treatment Landscape for Osteoporosis and EB613s Potential Impact on Wednesday, September 28th @ 10am ET (GlobeNewswire) +6.61%
Sep-12-22 04:30PM	Entera Bio to Present at H.C. Wainwright 24th Annual Global Investment Conference (GlobeNewswire)
06:30AM	Entera Bio Presents Dose Proportional Absorption and Correlation to BMD Clinical Response Data from its Phase 2 Study of EB613 in Post-Menopausal Osteoporosis Patients at the ASBMR 2022 Annual Meeting (GlobeNewswire)
Aug-11-22 06:30AM	Entera Bio Provides Business Highlights and Financial Results for the Second Quarter 2022 (GlobeNewswire)
Jul-26-22 07:30AM	Entera Bio Announces Formation of Clinical and Scientific Advisory Board and Poster Presentation at ASBMR 2022 Annual Meeting (GlobeNewswire) +6.82%
Jul-18-22 09:11AM	Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO (Benzinga)
07:05AM	Entera Bio Announces Execution of Key Regulatory Milestones for EB613, the First Oral Anabolic Drug Proposed for the Treatment of Osteoporosis; Miranda Toledano Assumes CEO Position (GlobeNewswire)
Jun-17-22 05:00PM	Entera Bio Announces Departure of Dr. Phillip Schwartz, the Companys President of Research & Development to Pursue Outside Opportunities (GlobeNewswire) -5.99%
May-16-22 08:00AM	Entera Bio Board Member, Miranda Toledano, to Assume Role of Chief Business Officer, Chief Financial Officer, and Head of Corporate Strategy (GlobeNewswire) +9.77%
May-12-22 08:00AM	Entera Bio Reports First Quarter 2022 Financial Results and Business Highlights (GlobeNewswire)
May-05-22 08:00AM	Entera Bio Files Patent Applications for Inventions that Optimize its Platform Technology for Oral Delivery of Large Molecule Therapeutics (GlobeNewswire)
Apr-28-22 08:00AM	Entera Bio to Report First Quarter 2022 Financial Results on May 12 (GlobeNewswire)
Apr-08-22 05:02PM	Recession Fears are Creating a Golden Opportunity for Biotech Stocks (InvestorPlace)
Mar-22-22 08:00AM	Entera Bio to Present at 2022 Maxim Virtual Growth Conference (GlobeNewswire)
Mar-16-22 06:14AM	Companies Like Entera Bio (NASDAQ:ENTX) Are In A Position To Invest In Growth (Simply Wall St.)
Mar-08-22 06:30AM	Entera Bio Reports Financial Results for the Year Ended December 31, 2021 (GlobeNewswire)
Mar-03-22 09:50AM	Entera Bio to Report Business and Financial Results for the Year Ended December 31, 2021 on March 8, 2022 (GlobeNewswire)
Feb-17-22 08:30AM	Entera Bio to Present at Aegis Virtual Conference on February 23rd (GlobeNewswire)
Jan-04-22 08:30AM	Entera Bio Announces Successful EB613 End-of-Phase 2 Meeting with FDA: FDA Agrees to Phase 3 Twelve Month Study with Lumbar Spine BMD (bone mineral density) as the Primary Endpoint (GlobeNewswire)
Nov-10-21 08:30AM	Entera Bio Reports Third Quarter 2021 Financial Results (GlobeNewswire) -5.96%
Oct-28-21 08:30AM	Entera Bio Publishes Key Study Describing its Oral Delivery Technology Platform for Biologic Drugs (GlobeNewswire) +5.45%
Oct-06-21 03:47PM	Entera Bio's Formulated Human Parathyroid Hormone Shows Encouraging BMD Data (Benzinga)
08:30AM	Entera Bio Presents Positive Phase 2 6-Month Bone Mineral Density Data for Oral PTH Formulation at Late Breaker ASBMR Conference Session (GlobeNewswire)
Sep-17-21 08:09AM	Entera Bio (NASDAQ:ENTX) Is In A Strong Position To Grow Its Business (Simply Wall St.)

Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of orally delivered large molecule therapeutics. It s pipeline include PTH, GLP-E, and hGh, The company was founded on September 30, 2009 and is headquartered in Jerusalem, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ENTX

Entera Bio Ltd

Upgrade your FINVIZ experience